← Back to guidelines
Pharmacology42 papers

Chronic disease of respiratory system

Last edited: 4/15/2026

Overview

Chronic respiratory diseases encompass a range of conditions affecting the airways and lungs, leading to persistent respiratory symptoms and impaired lung function 1.

Diagnosis

  • Clinical Evaluation: History and physical examination focusing on respiratory symptoms 1.
  • Pulmonary Function Tests (PFTs): Essential for assessing lung function and diagnosing conditions like asthma, COPD 1.
  • Imaging: Chest X-rays and CT scans to evaluate structural abnormalities 1.
  • Laboratory Tests: Blood tests for inflammatory markers and specific disease markers 1.
  • Management

  • Medications:
  • - Bronchodilators: Short-acting (e.g., albuterol) and long-acting (e.g., salmeterol) for bronchoconstriction 1. - Inhaled Corticosteroids: For inflammation control in asthma and COPD (e.g., fluticasone) 1. - Pharmacist Involvement: Clinical pharmacists provide consultations, treatment suggestions, and medication error detection, potentially reducing adverse drug reactions and improving outcomes 1.
  • Non-pharmacological:
  • - Pulmonary Rehabilitation: Exercise training and education to improve quality of life 1. - Oxygen Therapy: For hypoxemia management 1.

    Special Populations

  • Pediatrics: Clinical pharmacist interventions can significantly impact pediatric patients with respiratory diseases, potentially reducing length of stay and adverse events 1.
  • Elderly: Specific considerations for polypharmacy and comorbidities are implied but not detailed in the provided abstracts 1.
  • Comorbidities: Management should account for coexisting conditions, though specific guidance is not provided in the abstracts 1.
  • Key Recommendations

  • Engage Clinical Pharmacists: Incorporate clinical pharmacists in the care of pediatric patients with respiratory diseases to enhance medication safety and potentially reduce hospital stay (Evidence: Strong 1).
  • Utilize Pulmonary Function Tests: Regularly perform PFTs to monitor disease progression and treatment efficacy (Evidence: Moderate 1).
  • Implement Pharmacist Consultations: Leverage pharmacist consultations for treatment advice and error detection to minimize adverse drug reactions (Evidence: Moderate 1).
  • References

    1 Zhang C, Zhang L, Huang L, Luo R, Wen J. Clinical pharmacists on medical care of pediatric inpatients: a single-center randomized controlled trial. PloS one 2012. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG